Perspective Therapeutics Inc (AMEX:CATX)’s traded shares stood at 1.11 million during the last session, with the company’s beta value hitting 1.14. At the close of trading, the stock’s price was $3.28, to imply a decrease of -4.37% or -$0.15 in intraday trading. The CATX share’s 52-week high remains $16.55, putting it -404.57% down since that peak but still an impressive 51.22% since price per share fell to its 52-week low of $1.60.
Analysts have given a consensus recommendation of Buy for Perspective Therapeutics Inc (CATX), translating to a mean rating of 1.14. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CATX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.29.
Perspective Therapeutics Inc (AMEX:CATX) trade information
After registering a -4.37% downside in the last session, Perspective Therapeutics Inc (CATX) has traded red over the past five days. The 5-day price performance for the stock is 4.79%, and 30.68% over 30 days. With these gigs, the year-to-date price performance is 2.82%.
The extremes give us $3 and $24 for target low and target high price respectively. As such, CATX has been trading -631.71% off suggested target high and 8.54% from its likely low.
Perspective Therapeutics Inc (CATX) estimates and forecasts
The rating firms project that company’s revenue will shrink -37.34% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is 185.86k. Meanwhile, for the current quarter, a total of 11 analyst(s) estimate revenue growth to 177.72k.Earnings reports from the last fiscal year show that sales brought in 526k and 369k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -64.67% before dropping -51.84% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -9.86% for the past 5-year period. While 2025 is set for a 6.46% return in earnings, projections for the next 5 years are at -1.94% annually.
CATX Dividends
Perspective Therapeutics Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
